Johnson & Johnson (JNJ) said Tuesday that the US Food and Drug Administration has approved a simplified once-monthly dosing schedule for Rybrevant Faspro in combination with Lazcluze for first-line treatment of EGFR-mutated advanced non-small cell lung cancer.

The new schedule provides outcomes consistent with the previously approved bi-weekly subcutaneous regimen, the company said. Patients may transition to monthly dosing as early as Week 5, it added.

Rybrevant was recently approved as a subcutaneous formulation, reducing administration time from hours to minutes compared with intravenous delivery.